Paper Details

  1. Home
  2. Paper Details

Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.

Author: ChinWai, DonovanJoanne M, DufourRobert, EastCara, GagneClaude, GaudetDaniel, McGowanMary, SteinEvan A, TribbleDiane L

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Heterozygous familial hypercholesterolemia (HeFH) is a common genetic disorder leading to premature coronary artery disease. Mipomersen, an apolipoprotein B synthesis inhibitor, was evaluated to further lower LDL-C in HeFH patients with coronary artery disease.
Paper Details　
Original Abstract of the Article :
Heterozygous familial hypercholesterolemia (HeFH) is a common genetic disorder leading to premature coronary artery disease. Despite statins and additional lipid-lowering therapies, many HeFH patients fail to achieve low-density lipoprotein cholesterol (LDL-C) goals. We evaluated mipomersen, an apol...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1161/CIRCULATIONAHA.112.104125

データ提供：米国国立医学図書館（NLM）

Mipomersen: A New Oasis in the Desert of Cholesterol Management

This randomized, double-blind, placebo-controlled trial evaluates the efficacy and safety of mipomersen, an apolipoprotein B synthesis inhibitor, as add-on therapy in patients with heterozygous familial hypercholesterolemia (HeFH) and coronary artery disease (CAD). The researchers aim to determine whether mipomersen can effectively lower low-density lipoprotein cholesterol (LDL-C) levels in patients with HeFH and CAD who have not achieved their LDL-C goals with statins and other lipid-lowering therapies.

A Journey Through the Desert of Cholesterol: Seeking Effective Treatment Options

The study demonstrates that mipomersen can effectively lower LDL-C levels in patients with HeFH and CAD who have not achieved their LDL-C goals with traditional therapies. The researchers found that mipomersen significantly reduced LDL-C levels compared to placebo, suggesting that this agent may offer a valuable therapeutic option for patients with HeFH and CAD who require additional lipid-lowering therapy.

A Beacon of Hope: Navigating the Complexities of Cholesterol Management

This research highlights the importance of exploring innovative therapeutic approaches for managing cholesterol levels in patients with HeFH and CAD. The study’s findings suggest that mipomersen may offer a promising new avenue for lowering LDL-C levels, particularly in patients who have not achieved their goals with traditional therapies.

Dr. Camel's Conclusion

This study offers a glimmer of hope in the desert of cholesterol management. It suggests that mipomersen may be a valuable addition to the treatment arsenal for patients with HeFH and CAD, offering a potential solution for those who have not achieved their LDL-C goals with traditional therapies. This research encourages further exploration of the clinical applications of mipomersen, particularly in the context of managing cardiovascular risk and improving patient outcomes.

Date :
  1. Date Completed 2013-01-14
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

23060426

DOI: Digital Object Identifier

10.1161/CIRCULATIONAHA.112.104125

Related Literature

Article Analysis
・Effects of mipomersen injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.